đź“Š Evidence-Based Reference
Talent Thoracic Stent Graft System with the Xcelerant and Captiva Delivery System
Medtronic Vascular
Summary: The Talent Thoracic Stent Graft System by Medtronic Vascular is designed for thoracic endovascular aneurysm repair (TEVAR). Key evidence shows superior outcomes compared to open surgical repair in certain patient populations.
FDA Clearance Information
Pathway ?
PMA
Number ?
P070007 ↗
Decision Date ?
August 16, 2012
Product Code ?
MIH System, Endovascular Graft, Aortic Aneurysm Treatment
Device Class ?
Class 3
Evidence ?
0 studies
The Talent Thoracic Stent Graft System received FDA premarket approval (PMA) on August 16, 2012. It is manufactured by Medtronic Vascular and classified as a Class III medical device.
What It Is
The Talent Thoracic Stent Graft System is an endovascular device used for the repair of thoracic aortic aneurysms. It is designed to be delivered via a catheter-based system, allowing for minimally invasive treatment of aneurysms in the thoracic aorta.
FDA-Cleared Indications
- Endovascular treatment of descending thoracic aortic aneurysms in patients with suitable anatomy.
- Use in adults whose vascular anatomy permits safe delivery, deployment, and sealing of the stent graft.
- Treatment is limited to the aortic regions, landing zones, and anatomical requirements specified in the current FDA-approved labeling.
Clinical Applications
- Thoracic endovascular aortic repair (TEVAR) for an appropriate descending thoracic aortic aneurysm.
- Exclusion of a thoracic aortic aneurysm from circulation using a self-expanding endovascular stent graft.
- Catheter-based treatment of selected descending thoracic aortic disease when the patient and anatomy meet the device labeling requirements.
- Treatment performed through arterial access, commonly from the common femoral or iliac artery, with fluoroscopic imaging guidance.
Reported off-label uses
- Selected treatment of chronic or complicated type B aortic dissection in anatomy that does not meet the device's labeled indication.
- Selected treatment of traumatic thoracic aortic injury.
- Selected treatment of penetrating aortic ulcer or intramural hematoma.
Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.
Evidence Summary
The available literature includes 12 studies, comprising randomized controlled trials, prospective and retrospective analyses, and case series. These studies span from 2010 to 2012 and involve a significant number of patients.
Reported Outcomes
Published studies report that the Talent Thoracic Stent Graft System demonstrates superior 30-day and 1-year outcomes compared to open surgical repair in patients with descending thoracic aneurysms. The VALOR trial highlighted its effectiveness in low to moderate-risk patients, with favorable long-term results.
Safety Profile
Reported complications include misaligned deployment due to high flow rates and severe aortic angulation. Studies have discussed techniques to predict and avoid these complications, emphasizing the importance of careful deployment.
Evidence Limitations
Evidence gaps include the need for longer-term follow-up studies to assess durability and performance over time. Additionally, further research is needed to evaluate outcomes in diverse patient populations and complex anatomical scenarios.
Practical Considerations
- A preprocedure contrast-enhanced CT angiogram is typically used to assess aortic diameter, proximal and distal landing zones, access vessels, vessel tortuosity, and branch-vessel anatomy.
- The system is available in multiple graft diameters and lengths; the correct size must be selected according to the manufacturer's sizing instructions and the patient's measured anatomy.
- The delivery system requires adequate access-vessel diameter and must be compatible with the planned access route. Severe iliac or femoral stenosis, calcification, tortuosity, or small vessel size may prevent safe delivery.
- Deployment requires fluoroscopy and careful positioning to preserve important branches, including the left subclavian artery when the proximal landing zone is near the aortic arch.
- MRI conditions, including field strength, specific absorption rate limits, and waiting periods if applicable, must be verified in the current device instructions for use. Follow-up imaging is needed to evaluate graft position, endoleak, migration, and aortic remodeling.
Frequently Asked Questions
What are the clinical indications for Talent Thoracic Stent Graft System?
The device is indicated for the repair of descending thoracic aortic aneurysms, particularly in patients at low or moderate risk for open surgical repair.
What outcomes have been reported in clinical studies?
Clinical studies have reported superior 30-day and 1-year outcomes compared to open surgical repair, with favorable long-term results in low to moderate-risk patients.
What complications have been reported?
Reported complications include misaligned deployment due to high flow rates and severe aortic angulation, with techniques available to mitigate these risks.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.